Table 5 Summary of echocardiographic left ventricular ejection fraction (LVEF) and shortening fraction
Placebo (N = 116) | Tadalafil 0.3 mg/kg (N = 102) | Tadalafil 0.6 mg/kg (N = 112) | |
|---|---|---|---|
LVEF, % | |||
Baseline mean (SD) | 63.5 (6.4) | 63.2 (5.6) | 62.4 (6.8) |
LS mean change at Week 24 (SE)a | -1.0 (0.5) | -1.2 (0.5), p =.857 | -0.6 (0.5), p =.548 |
LS mean change at Week 48 (SE)a | -1.5 (0.6) | -0.3 (0.6), p =.127 | -0.7 (0.6), p =.302 |
LV Shortening Fraction, % | |||
Baseline mean (SD) | 35.0 (6.3) | 35.5 (5.2) | 34.7 (5.5) |
LS mean change at Week 24 (SE)a | -0.5 (0.4) | -1.1 (0.5), p =.307 | -0.4 (0.4), p =.929 |
LS mean change at Week 48 (SE)a | -0.3 (0.6) | -0.5 (0.6), p =.824 | 0.1 (0.6), p =.631 |